Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Post by MomenTomon Aug 23, 2021 9:26am
278 Views
Post# 33747675

Pfizer acquires Trillium 2.26 billion deal (18.50$ / share)

Pfizer acquires Trillium 2.26 billion deal (18.50$ / share)

Aug 23 (Reuters) - Pfizer Inc said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies.

Pfizer, which acquired a $25 million stake in Trillium last year, will buy the remaining outstanding shares for $18.50 apiece, representing a 203.8% premium on the stock's last closing price.

 

Pfizer expects to benefit from Canada-based Trillium's blood-cancer therapies that target a "don't eat me" signal used by cancer cells to evade the immune system.

Forty Seven Inc, which is also developing drugs that target the same antibodies, was bought by Gilead Sciences Inc for $4.9 billion last year.

More than 1 million people worldwide were diagnosed with blood cancer in 2020, representing almost 6% of all cancer diagnoses. The same year, more than 700,000 people worldwide died from a form of blood cancer.

Trillium's U.S.-listed shares were trading at $17.73 before the bell on Monday, having fallen 59% in 2021 as of their last close. Pfizer bought nearly 2.3 million Trillium shares at $10.88 each in September.

Pfizer's financial adviser for the transaction is BofA Securities Inc, and Centerview Partners LLC is Trillium's. (Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila and Shinjini Ganguli)

<< Previous
Bullboard Posts
Next >>